Our findings imply that the evolution of HER2-low expression from primary to recurrent tumors within the HoR-positive breast cancer involves a non-negligible proportion of HER2-negative breast cancer patients, thus warranting further investigation. The gene discussed is ERBB2; the disease is breast cancer.